Brief: Adaptive Biotechnologies Announces Launch Of Clonoseq® To Assess Minimal Residual Disease (Mrd) In Patients With Diffuse Large B-Cell Lymphoma (Dlbcl) Using Circulating Tumor Dna (Ctdna)
01/12/2022 12:31
Dec 1 (Reuters) - Adaptive Biotechnologies Corp
ADPT.O :
* ADAPTIVE BIOTECHNOLOGIES ANNOUNCES LAUNCH OF CLONOSEQ® TO
ASSESS
MINIMAL RESIDUAL DISEASE (MRD) IN PATIENTS WITH DIFFUSE LARGE
B-CELL LYMPHOMA (DLBCL) USING CIRCULATING TUMOR DNA (CTDNA)
Source text for Eikon: ID:nGNX76RY0k
Further company coverage: ADPT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Adaptive Biotechnologies
See all newsAdvisory: Alert incorrectly tagged to Adaptive Biotechnologies withdrawn
U.S. RESEARCH ROUNDUP-Cloudflare, Replimune, Walmart
U.S. RESEARCH ROUNDUP-Equinix, Meta, S&P Global
Adaptive Biotechnologies Corp reports results for the quarter ended June 30 - Earnings Summary
Adaptive Biotechnologies Q2 revenue rises 22%, beats estimates